The Changing Mutational Landscape of Acute Myeloid Leukemia and Myelodysplastic Syndrome
- 1 August 2013
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 11 (8), 815-827
- https://doi.org/10.1158/1541-7786.mcr-12-0695
Abstract
Over the past few years, large-scale genomic studies of patients with myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) have unveiled recurrent somatic mutations in genes involved in epigenetic regulation (DNMT3A, IDH1/2, TET2, ASXL1, EZH2 and MLL) and the spliceosomal machinery (SF3B1, U2AF1, SRSF2, ZRSR2, SF3A1, PRPF40B, U2AF2, and SF1). The identification of these mutations and their impact on prognostication has led to improvements in risk-stratification strategies and has also provided new potential targets for the treatment of these myeloid malignancies. In this review, we discuss the most recently identified genetic abnormalities described in MDS and AML and appraise the current status quo of the dynamics of acquisition of mutant alleles in the pathogenesis of AML, during the transformation from MDS to AML, and in the context of relapse after conventional chemotherapy. Implications: Identification of somatic mutations in AML and MDS suggests new targets for therapeutic development. Mol Cancer Res; 11(8); 815–27. ©2013 AACR.Keywords
This publication has 78 references indexed in Scilit:
- The Origin and Evolution of Mutations in Acute Myeloid LeukemiaCell, 2012
- Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disordersLeukemia, 2012
- Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 MutationsCell, 2012
- The Spliceosome as an Indicted Conspirator in Myeloid MalignanciesCancer Cell, 2011
- Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid TransformationCancer Cell, 2011
- Use of Whole-Genome Sequencing to Diagnose a Cryptic Fusion OncogeneJAMA, 2011
- Identification of a Novel TP53 Cancer Susceptibility Mutation Through Whole-Genome Sequencing of a Patient With Therapy-Related AMLJAMA, 2011
- Recurrent DNMT3A mutations in patients with myelodysplastic syndromesLeukemia, 2011
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent DioxygenasesCancer Cell, 2011
- Zscan4 regulates telomere elongation and genomic stability in ES cellsNature, 2010